IQVIA and Veeva Form Long-term Partnerships, Resolve All Disputes

IQVIA and Veeva Systems have announced long-term partnerships to improve clinical trial execution and commercial product offerings. The partnerships resolve all existing legal disputes between the two companies and enable mutual usage of their data and software through master data and software third-party access agreements. IQVIA is now a member of Veeva's CRO Clinical Data Partner program, and Veeva data can be used within IQVIA's commercial products and services.

IQVIA (NYSE: IQV) and Veeva Systems (NYSE: VEEV) have entered into long-term clinical and commercial partnerships, resolving all existing legal disputes and enabling mutual usage of their data and software through master data and software third-party access agreements. The collaboration aims to improve clinical trial execution and commercial product offerings for their shared clients.

Under the terms of the agreement, customers can now leverage software, data, technology, and service offerings from both companies in a streamlined and efficient manner. Key areas of collaboration include commercial and clinical aspects:

- Commercial: The companies have established master data and software third-party access (TPA) agreements, allowing IQVIA or Veeva data to be used with each other's software or services in customer instances. This includes the use of IQVIA data in Veeva Network for master data management (MDM), Veeva Nitro for analytics, and Veeva AI. Additionally, IQVIA has joined the Veeva Technology, AI, and Services Partner Programs to support customer integrations between Veeva software and IQVIA Analytics, IQVIA Information Management (including MDM), IQVIA Agentic AI, and IQVIA Commercial Orchestration offerings.

- Clinical: IQVIA has joined Veeva's CRO Clinical Data Partner program and can leverage the Veeva Clinical Suite to execute clinical trials using Veeva software products, including study builds with Veeva EDC. This partnership will benefit customers by accelerating database builds, study locks, and data delivery, thanks to IQVIA's clinical data management and technology solutions.

Peter Gassner, Veeva founder and CEO, stated, "We are committed to supporting frictionless product and services integration with IQVIA for the benefit of our joint customers and the industry overall. I am excited about the potential for our clinical and commercial partnerships to create significant value for our shared customers."

Ari Bousbib, chairman and CEO of IQVIA, added, "IQVIA and Veeva's partnerships bring together best-in-class capabilities in information, AI, technology, and services for our shared clients. This will enable IQVIA customers on Veeva platforms to accelerate clinical development, bring treatments to market more efficiently, and improve access to innovations for patients."

These strategic partnerships align with the growing demand for advanced eClinical solutions, as highlighted in a recent market assessment report [2]. The report estimates that the eClinical Solutions Market is expected to reach over USD 35.0 Bn by 2034, with a CAGR of 11.8% during the forecast period. The market is driven by the increasing complexity of clinical trial methodologies, the growing reliance on CROs, and escalating investments in pharmaceutical and biopharmaceutical research and development.

References:

[1] https://www.prnewswire.com/news-releases/iqvia-and-veeva-announce-long-term-clinical-and-commercial-partnerships-and-resolution-of-all-disputes-302531711.html

[2] https://www.openpr.com/news/4141179/eclinical-solutions-market-key-players-analysis-medidata